Sierra Oncology Declares 1-for-40 Reverse Stock Split
January 22 2020 - 6:49AM
Dow Jones News
By Chris Wack
Sierra Oncology Inc. (SRRA) said its board of directors has
approved a reverse stock split of its shares of common stock at a
ratio of 1-for-40, effective after the market closes Wednesday.
The company said shortly following the reverse stock split, the
series A convertible voting preferred stock issued in the recently
completed $103 million financing will be converted into shares of
common stock, and Gilead Sciences Inc. (GILD) will be issued
725,000 shares of common stock on a post-split basis and a warrant
to purchase an equivalent amount of common stock, in consideration
for amending the royalty rates and milestones in an asset purchase
agreement with Gilead for momelotinib.
Sierra Oncology said its cash and cash equivalents totaled $67.7
million as of Sept. 30, and that subsequently it had closed an
underwritten public offering with gross proceeds to Sierra Oncology
of $103 million.
Sierra Oncology shares were up 5%, to 41 cents, premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 22, 2020 07:34 ET (12:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Apr 2024 to May 2024
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sierra Oncology Inc (NASDAQ): 0 recent articles
More Sierra Oncology Inc News Articles